The Ministry of Health and Welfare has approved a clinical research plan for personalized immune-cell therapy in patients with terminal colorectal cancer. The decision was made on October 22 at the 11th meeting of the Committee for Advanced Regenerative Medicine and Advanced Biopharmaceuticals. Three plans submitted by regenerative-medicine institutions were reviewed, with one judged suitable and two judged unsuitable.

The approved study will enroll patients with metastatic or recurrent stage 4 colorectal cancer whose standard treatments have failed. Researchers will collect each participant’s blood, culture the patient’s own T lymphocytes and natural killer cells, and administer the two cell types sequentially. The study will assess safety, disease-control rate and progression-free survival.

The target disease includes cancer that has spread to organs such as the liver, lungs or peritoneum. For patients who no longer respond to surgery, targeted therapy or other established options, treatment choices can be limited. T lymphocytes can attack cancer or infected cells and regulate other immune cells, while natural killer cells recognize and remove abnormal cells.

The committee’s decision confirms that the research plan met its review requirements. It does not show that the therapy is effective, nor does it make the treatment available as an approved standard therapy. The committee said its review was intended to assess scientific grounds and safety while creating additional research opportunities for patients with difficult-to-treat diseases.